The FDA's Drugs@FDA database recorded a supplement on 20 October to NDA 217806, the application for tirzepatide marketed as Zepbound for weight management.
The record does not specify what the supplement covers. Supplements can concern a labelling change, a new indication, a new dose or presentation, or manufacturing. Until the label is updated, there is no basis for changing prescribing.
Check the current FDA label before relying on any reported change. The regulatory position in India, including CDSCO's view of any change, is not stated in this record.
- Check the updated Zepbound label on the FDA site before acting on any reported change
- Do not assume a new indication from a supplement record alone
- Confirm the local regulatory status before applying a US label change in India
Why it matters
Label changes to widely used incretin drugs can affect dosing and safety advice.
Don't overread it
A licence supplement is not a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free